New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
08:21 EDTENDP, TEVA, PATHNuPathe up 36% to $4.40 after receiving rival Teva bid
Teva (TEVA) offered to purchase any and all of the shares of NuPathe (PATH) for $3.65 per share, net to the seller in cash, plus contractual rights to receive up to an additional $3.15 per share in contingent cash consideration payments payable in the future upon achievement of certain milestones related to NuPathe's migraine treatment ZECUITY. In December, Endo Health Solutions (ENDP) entered into a definitive agreement to acquire NuPathe for $2.85 per share in cash plus rights to receive additional cash payments of up to $3.15 per share based on net sales of ZECUITY. Shares of NuPath are up about 36% in pre-market trade following its disclosure of the rival bid made by Teva.
News For PATH;TEVA;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
10:05 EDTENDPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:03 EDTTEVATeva announces U.S. availability of Zecuity transdermal patch system
Subscribe for More Information
07:11 EDTENDPMorgan Stanley ups Alkermes two notches with $85 price target
Subscribe for More Information
06:39 EDTENDPEndo downgraded to Equal Weight on growth uncertainty at Morgan Stanley
Subscribe for More Information
06:28 EDTENDPEndo downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
August 31, 2015
08:02 EDTENDPEndo announces Xiaflex for Dupuytren's contracture formal pricing in Japan
Endo announced that XIAFLEX for the treatment of Dupuytren's contracture has been listed on the Japanese National Health Insurance drug price standard. As a result, Endo partner Asahi Kasei Pharma expects to commercially launch the product in Japan on September 16, 2015. Under the terms of the partnership agreement, Endo will receive a $20M milestone payment upon the first commercial sale of XIAFLEX in Japan. In March 2011, Asahi Kasei Pharma received rights to develop and market XIAFLEX in Japan through an agreement with Auxilium Pharmaceuticals, which was subsequently acquired by Endo in January 2015. Under the agreement, Asahi Kasei Pharma was granted the exclusive right to commercialize XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease in Japan upon receipt of applicable regulatory approvals. Asahi Kasei Pharma is also responsible for clinical development and regulatory activities for XIAFLEX and has a right of first negotiation to obtain exclusive rights to commercialize other XIAFLEX(R) pipeline indications in Japan. Endo is eligible to receive up to $217M in remaining potential milestone payments and up to $210M in connection with the achievement of aggregate annual net sales thresholds. In addition, Asahi Kasei Pharma will provide tiered payments based on net sales of XIAFLEX . Asahi Kasei Pharma obtained approval in Japan for the manufacture and marketing of XIAFLEX(R) for Dupuytren's contracture in July 2015.
05:59 EDTTEVAStocks with implied volatility below IV index mean; BIIB TEVA
Stocks with implied volatility below IV index mean; Biogen (BIIB) 37, Teva (TEVA) 31 according to iVolatility.
August 28, 2015
09:50 EDTENDPAllergan plans for generic version of Endo's Fortesta blocked, Bloomberg reports
A judge upheld Endo's (ENDP) patents on Fortesta expiring in 2018 and blocked Allergan's (AGN) bid to launch a generic version of the testosterone gel, according to Bloomberg.
06:01 EDTTEVAStocks with implied volatility below IV index mean; BIIB TEVA
Stocks with implied volatility below IV index mean; Biogen (BIIB) 38, Teva (TEVA) 31 according to iVolatility.
August 27, 2015
06:01 EDTTEVAStocks with implied volatility below IV index mean; BBY TEVA
Stocks with implied volatility below IV index mean; Best Buy (BBY) 34, Teva (TEVA) 33 according to iVolatility.
August 26, 2015
05:56 EDTTEVAStocks with implied volatility below IV index mean; BBY TEVA
Subscribe for More Information
August 25, 2015
17:11 EDTTEVAU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information
15:02 EDTTEVAMylan says USPTO institutes IPR of two Copaxone patents
Subscribe for More Information
14:40 EDTTEVATeva Copaxone patents to be reconsidered by regulators, Bloomberg says
11:27 EDTTEVATeva to refrain from voting at Mylan special meeting
Subscribe for More Information
08:17 EDTTEVATeva multiple low, says Leerink
Subscribe for More Information
August 24, 2015
10:20 EDTTEVATeva says EMA confirms validation of reslizumab MAA
Subscribe for More Information
August 21, 2015
05:51 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Stocks with implied volatility below IV index mean; Teva (TEVA) 25, Keurig Green Mountain (GMCR) 39 according to iVolatility.
August 20, 2015
05:58 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Stocks with implied volatility below IV index mean; Teva (TEVA) 23, Keurig Green Mountain (GMCR) 37 according to iVolatility.
05:57 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use